Time-Related Biases in Nonrandomized COVID-19–Era Studies Using Real-world Data
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The urgent response to the COVID-19 pandemic has highlighted the importance of diverse, real-world data sources, such as electronic health records, insurance claims, and patient registries, to further inform evidence-based care amid an evolving public health crisis. Real-world data have the potential to provide a wealth of rapid, actionable information and inform ongoing work to evaluate the effectiveness and safety of potential therapies, vaccines, or diagnostics for COVID-19.
Having cancer was recognized early as a potential risk factor for severe illness associated with COVID-19 given the increased likelihood of having a weakened immune system and frequent multimorbidity observed among patients with cancer. Patients with hematologic cancer often have abnormal or depleted levels of immune cells that produce antibodies against viruses and may be at higher risk of prolonged infection and death from COVID-19 relative to patients with solid tumors.
JAMA Oncology , éditorial, 2020